Premium
The relationship between cardiovascular complications of estrogen therapy and fibrinolysis in patients with prostatic cancer
Author(s) -
Hasui Yoshihiro,
Nishi Shohei,
Kitada Shinichiro,
Osada Yukio,
Sumiyoshi Akinobu,
Marutsuka Kousuke
Publication year - 1992
Publication title -
the prostate
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.295
H-Index - 123
eISSN - 1097-0045
pISSN - 0270-4137
DOI - 10.1002/pros.2990210104
Subject(s) - medicine , fibrinolysis , estrogen , plasminogen activator , cancer , t plasminogen activator , tissue plasminogen activator , endocrinology , urokinase , prostate cancer , hormone therapy , estrogen therapy , gastroenterology , breast cancer
To determine the relationship between cardiovascular complications of estrogen therapy and fibrinolysis, fibrinolysis parameters plasminogen, urokinase‐type plasminogen activator (u‐PA), tissue‐type plasminogen activator (t‐PA), and plasminogen activator inhibitor‐1 (PAI‐1), were assessed in 12 prostatic cancer patients before and 6 weeks after the onset of estrogen therapy. The levels of plasminogen, u‐PA, and PAI‐1 in the patients treated with the estrogen therapy were significantly higher than those in the patients before the therapy. The t‐PA level in the patients during the therapy was significantly lower than that before the treatment. Cardiovascular complications were found in two patients (16.7%) during estrogen therapy. In the two patients, marked elevation of PAI‐1 and decreased level of t‐PA were observed during the therapy. These results indicate that cardiovascular complications of estrogen therapy in patients with prostatic cancer may be related to hypofibrinolysis resulting from changes of PAI and t‐PA.